Is Japan’s real value still in ‘Value’
5 min read
By Alex Bowles About the author >>

Key takeaways
01 Japan’s Value discount has narrowed
Governance reform, a weak yen and higher interest rates drove a powerful re-rating in Japan’s cheapest shares, but their relative discount has narrowed significantly.
02 Value can be expensive and Growth can be cheap
Some former Value winners now trade at demanding valuations, while strong Growth compounders left behind by the market may now offer more attractive discounts.
03 Price matters more than style
Finding real value means understanding what a business is worth and what investors are being asked to pay for it, regardless of whether it’s a Value or Growth stock.
...stripping Japan out of the World Index strips out almost all of the outperformance of Value over Growth globally.
Japanese ‘Value’ stocks have had a remarkable run. Since 2021, buying Japan’s cheapest stocks has been a highly rewarding strategy, as corporate governance reform, a weak yen and the return of positive interest rates have combined to lift the market’s cheapest names.
As we look ahead to 2027, the question investors should be asking is whether the Value label is still a reliable guide to where Japan’s discounts are. After five years of re-rating, many of the stocks that once screened as cheap now look to be more richly valued, while some of the market’s strongest compounders have been left behind.
Japan’s Value run
Over long periods, Value investing–that is, buying stocks that trade at low multiples of earnings or book value–has proven to be a rewarding trade in Japan.
Since 1975, simply buying Japan’s cheapest stocks would have outperformed a ‘Growth’ approach–buying shares in companies that are able to compound earnings at a faster rate, but typically trade on richer multiples of those earnings–by 4.7% per annum*.
Value investing has been such a successful strategy in Japan over the past 50 years that stripping Japan out of the MSCI World Index strips out almost all of the outperformance of Value over Growth globally.
Value has historically outperformed Growth by more in Japan than globally Cumulative relative returns of MSCI Value vs Growth indices
Click to expand
30 Sep 2026 | Source: LSEG Datastream, Orbis. Total relative returns for MSCI indices, gross of withholding tax, calculated geometrically, rebased to 100 at 1 Jan 1975.
Growth investing has had its moments, most notably in the post-global-financial-crisis era to its Covid peak, a period of over ten years. But since then, unlike in many other markets, Japanese Value has roared back into fashion.
Several factors have combined to give Japan’s Value names a boost: the Tokyo Stock Exchange’s push for better capital allocation has caused many of the cheapest stocks to re-rate; a hunt for both AI beneficiaries and for businesses immune from AI disruption has revived many industrials; a weak yen has flattered exporters’ earnings; and an end to zero (or indeed negative!) interest rates has helped the banks, and raised the premium on companies’ cash flows today over promised growth tomorrow.
In 2021, Value stocks were cheaper relative to Growth stocks than at almost any point in history.
Why the Value label is now misleading
In 2021, Value stocks were cheaper relative to Growth stocks than at almost any point in history, which set the stage for their run. That discount has since narrowed meaningfully, and many Value names are no longer the bargains they once were.
Value is no longer at extreme levels of cheapness vs Growth Relative attractiveness of TOPIX 500 Value vs Growth shares
30 Sep 2026 | Source: LSEG Datastream, Orbis. Value (Growth) shares are those in the cheapest (richest) half of the market on a price-to-book basis. Relative attractiveness is based on the book-to-price ratio of the relevant market segments. Statistics are compiled from an internal research database and are subject to subsequent revision due to changes in methodology or data cleaning.
In our view, what matters most is the price paid for the fundamentals of a business, rather than the label applied to it. Through that lens, investors may find that some of Japan’s Growth names, those that are fundamentally strong but have underperformed, now offer a wider discount to intrinsic value than many of yesterday’s Value winners.
Two examples illustrate this.
A tale of two stocks
First, Mitsubishi Corporation. The largest of Japan’s trading companies, Mitsubishi is a vast conglomerate spanning virtually every major industry and touches almost every part of Japan’s economy. For many years, it was a classic Value stock, on a single-digit price-to-earnings multiple and a low price-to-book. But since mid-2020, its share price has risen more than fivefold, with returns to rival even the raciest Growth names. So what changed? Did Mitsubishi transform itself into a high-growth earnings compounder?
No, not especially. Profits did rise from the Covid trough, but growth has slowed meaningfully. Where the company has improved, however, is on capital allocation and shareholder returns. A ringing endorsement from Warren Buffett also helped: in 2020, Berkshire Hathaway announced it had built substantial stakes in five of Japan’s largest trading companies.
At its peak in March 2026, Mitsubishi shares traded on close to 25 times next year’s earnings. Not bad for a sleepy Japanese Value stock.
Our second example, GMO Payment Gateway, is a payment services provider with a track record of having compounded earnings by 25% per annum over the past ten years. GMO PG is a relatively young, tech-focused company, led by an entrepreneurial management team, with a long runway for future growth. In 2021, the market was clearly sold on GMO PG’s growth story, and shares in the company changed hands at an eye-watering 125 times earnings.
Since then, returns have proved disappointing. The stock halved over the next two years, and has gone almost nowhere since. So what happened to GMO PG? Did the growth story that investors bought into in 2021 turn out to be elusive?
No, not really. The company has continued to compound earnings at a healthy clip, and the outlook for future growth continues to look bright, with rising e-commerce penetration and a shift to cashless payments in Japan. With the shares now valued at around 22 times next year’s earnings*, GMO PG appears to us to represent excellent value.
Finding real value means asking what a business is worth and what we are being asked to pay for it, regardless of in which bucket it sits.
A tale of two stocks: Mitsubishi and GMO Payment Gateway
30 Sep 2026 | Source: LSEG Datastream, I/B/E/S Estimates, Orbis. FY2022 reported earnings for GMO Payment Gateway include an adjustment to exclude gains on a sale of an equity affiliate.
Mitsubishi is a Value stock that is no longer cheap. GMO Payment Gateway is a Growth stock that is no longer expensive. A simplistic style label wouldn’t have told you that, only an assessment of the price paid relative to what the business can earn would have.
What investors should be thinking about in 2027
So is Japan’s real value still in ‘Value’? Not reliably, and not by default. Discounts can still be found, but they no longer sit neatly where the label points, and investors who remain fixated on simplistic definitions of value risk crowding into yesterday’s winners. Finding real value means asking what a business is worth and what we are being asked to pay for it, regardless of which bucket it sits in.
*Data as at 30 September 2026
Keep exploring our six questions for 2027
FTSE: London Stock Exchange Group plc and its group undertakings (collectively, the “LSE Group”). © LSE Group 2026. FTSE Russell is a trading name of certain of the LSE Group companies. “FTSE®” “Russell®”, “FTSE Russell®”, “FTSE4Good®”, “ICB®”, are trade marks of the relevant LSE Group companies and is/are used by any other LSE Group company under license. All rights in the FTSE Russell indexes or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indexes or data and no party may rely on any indexes or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company’s express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication.
S&P Capital IQ: Copyright © 2026 S&P Global Market Intelligence. All rights reserved. S&P Global Market Intelligence, its affiliates and third-party providers (collectively, “S&P Global”) do not guarantee the accuracy, completeness, availability or timeliness of the content and are not responsible for any errors or omissions or for results obtained from its use. The content is provided on an “as is” basis and does not constitute investment advice or a recommendation to buy, sell or hold any security or make any investment decision. No copying, reproduction or further distribution of the S&P Global content is permitted without prior written consent. Nothing in this communication should be taken as implying sponsorship or endorsement by S&P Global.
Jefferies: © 2026 Jefferies LLC. All rights reserved. Information supplied by Jefferies LLC has been obtained from sources believed to be reliable, but Jefferies LLC does not guarantee its accuracy, completeness or timeliness and accepts no responsibility for errors or omissions or for results obtained from its use. The information is provided for informational purposes only and does not constitute investment advice, an offer or solicitation, or a recommendation to buy, sell or hold any security or other financial instrument. Any opinions or estimates are given as at their stated date and may change without notice. Material excerpted or summarised from Jefferies research remains subject to the disclaimers and disclosures contained in the relevant research report. No Jefferies content may be reproduced or redistributed without prior written consent.
Important information
For financial advisers and wholesale client investors only. Past performance is not a reliable indicator of future results. This constitutes general information only and not personal financial product, tax, legal, or investment advice, and does not take into account the specific investment objectives, financial situation or individual needs of any particular person. This should not under any circumstances be construed as an opinion or recommendation to invest in any financial product or to adopt any investment strategy.
This report represents Orbis' view at a point in time and provides reasoning or rationale on why we bought or sold a particular security for the Orbis Funds. We may take the opposite view/position from that stated in this report. This is because our view may change as facts or circumstances change. This report does not prohibit the Orbis Funds from dealing in the securities before or after this document is published. The value of investments in the Orbis Funds may fall as well as rise and you may get back less than you originally invested. It is therefore important that you understand the risks involved before investing.
Equity Trustees Limited AFSL No. 240975 ABN 46 004 031 298 (EQT) is the responsible entity for and issuer of units in the Orbis Funds domiciled in Australia. You should consider such funds’ Product Disclosure Statement (PDS) or Information Memorandum (IM) and Target Market Determinations (TMDs), as applicable, before acquiring or disposing units in such funds. The PDS, IM and TMD can be obtained from www.orbis.com.au. Each TMD sets out who an investment in the relevant Fund might be appropriate for and the circumstances that trigger a review of the TMD.




